JANX RSI Chart
Last 7 days
-3.6%
Last 30 days
-1.6%
Last 90 days
400.2%
Trailing 12 Months
274.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 14.6M | 0 | 0 | 0 |
2023 | 6.7M | 9.6M | 10.3M | 16.2M |
2022 | 3.4M | 3.3M | 3.9M | 4.0M |
2021 | 0 | 0 | 0 | 3.6M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Feb 29, 2024 | avalon ventures xi, l.p. | sold | - | - | -438,722 | - |
Feb 29, 2024 | avalon ventures xi, l.p. | acquired | - | - | 31,456 | - |
Feb 29, 2024 | avalon ventures xi, l.p. | sold | - | - | -31,456 | - |
Feb 29, 2024 | avalon ventures xi, l.p. | acquired | - | - | 1,700 | - |
Feb 29, 2024 | avalon ventures xi, l.p. | sold | - | - | -1,700 | - |
Feb 29, 2024 | avalon ventures xi, l.p. | sold | - | - | -84,985 | - |
Feb 29, 2024 | avalon ventures xi, l.p. | sold | - | - | -447,949 | - |
Feb 29, 2024 | avalon ventures xi, l.p. | acquired | - | - | 11,388 | - |
Feb 29, 2024 | avalon ventures xi, l.p. | sold | - | - | -11,388 | - |
Feb 29, 2024 | gujrathi sheila | acquired | - | - | 2,986 | - |
Which funds bought or sold JANX recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | new | - | 1,882,500 | 1,882,500 | 0.05% |
May 16, 2024 | JANE STREET GROUP, LLC | new | - | 757,970 | 757,970 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -5.4 | 427,832 | 612,302 | -% |
May 15, 2024 | GILDER GAGNON HOWE & CO LLC | new | - | 436,401 | 436,401 | -% |
May 15, 2024 | RA CAPITAL MANAGEMENT, L.P. | unchanged | - | 246,739,000 | 345,087,000 | 4.39% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | reduced | -46.25 | 416,333 | 886,319 | -% |
May 15, 2024 | Driehaus Capital Management LLC | new | - | 7,193,220 | 7,193,220 | 0.07% |
May 15, 2024 | BARCLAYS PLC | reduced | -67.52 | 73,000 | 584,000 | -% |
May 15, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | new | - | 739,000 | 739,000 | -% |
May 15, 2024 | WELLINGTON MANAGEMENT GROUP LLP | new | - | 1,189,550 | 1,189,550 | -% |
Unveiling Janux Therapeutics, Inc.'s Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Janux Therapeutics, Inc.)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Janux Therapeutics, Inc. News
Income Statement (Quarterly) | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 |
Revenue | -83.5% | 1,252 | 7,586 | 2,517 | 3,240 | 2,822 | 1,714 | 1,813 | 373 | 132 | 1,616 | 1,159 | 482 | 380 |
Operating Expenses | 15.1% | 21,413 | 18,598 | 18,330 | 21,805 | 22,329 | 21,111 | 19,835 | 19,626 | 15,131 | 15,106 | 12,062 | 6,734 | 2,664 |
S&GA Expenses | -100.0% | - | 6,357 | 6,438 | 6,881 | 6,464 | 5,677 | 6,098 | 5,540 | 4,947 | 3,937 | 3,656 | 1,997 | 739 |
R&D Expenses | 14.9% | 14,070 | 12,241 | 11,892 | 14,924 | 15,865 | 15,434 | 13,737 | 14,086 | 10,184 | 11,169 | 8,406 | 4,737 | 1,925 |
Net Income | -25.5% | -14,760 | -11,758 | -11,568 | -17,508 | -17,459 | -16,065 | -16,696 | -16,888 | -13,410 | -13,416 | -10,766 | -6,206 | -2,284 |
Net Income Margin | -5.6% | -3.81* | -3.61* | -6.08* | -7.06* | -9.98* | -15.64* | -15.36* | -16.61* | -12.92* | -8.98* | - | - | - |
Free Cashflow | -44.3% | -15,034 | -10,416 | -12,179 | -15,634 | -14,196 | -13,969 | -15,934 | -6,971 | -12,493 | -11,654 | -5,931 | -6,283 | 5,410 |
Balance Sheet | ||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
Assets | 81.1% | 689 | 380 | 387 | 342 | 353 | 364 | 376 | 385 | 369 | 380 | 391 | 397 | - |
Current Assets | 88.6% | 659 | 349 | 355 | 309 | 321 | 332 | 344 | 358 | 365 | 377 | 390 | 397 | 16.00 |
Cash Equivalents | 1008.1% | 213 | 19.00 | 17.00 | 34.00 | 30.00 | 51.00 | 65.00 | 58.00 | 55.00 | 36.00 | 39.00 | 252 | 8.00 |
Net PPE | -6.9% | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 7.00 | 4.00 | 3.00 | 1.00 | 1.00 | 0.00 | 0.00 |
Liabilities | -7.9% | 33.00 | 36.00 | 38.00 | 42.00 | 42.00 | 43.00 | 44.00 | 42.00 | 13.00 | 13.00 | 14.00 | 12.00 | 9.00 |
Current Liabilities | -18.6% | 11.00 | 13.00 | 14.00 | 18.00 | 16.00 | 17.00 | 16.00 | 13.00 | 13.00 | 13.00 | 12.00 | 9.00 | 3.00 |
Shareholder's Equity | 90.4% | 656 | 344 | 349 | 299 | 311 | 321 | 332 | 344 | 356 | 366 | 377 | 385 | - |
Retained Earnings | -8.7% | -183 | -168 | -157 | -145 | -127 | -110 | -94.40 | -77.71 | -60.82 | -47.41 | -34.00 | -23.23 | -14.74 |
Additional Paid-In Capital | 63.9% | 840 | 512 | 507 | 446 | 440 | 433 | 428 | 423 | 418 | 414 | 411 | 408 | 0.00 |
Shares Outstanding | 12.1% | 52.00 | 46.00 | 46.00 | 42.00 | 42.00 | 42.00 | 41.00 | 41.00 | 41.00 | 41.00 | 18.00 | 10.00 | - |
Float | - | - | - | - | 280 | - | - | - | 205 | - | - | - | 526 | - |
Cashflow (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 |
Cashflow From Operations | -49.9% | -14,837 | -9,901 | -11,709 | -15,054 | -13,911 | -11,913 | -13,414 | -6,073 | -11,522 | -10,481 | -5,854 | -6,204 | 5,563 | - | - | - |
Share Based Compensation | 25.5% | 5,625 | 4,483 | 4,548 | 5,501 | 5,473 | 4,205 | 4,596 | 4,444 | 3,958 | 2,944 | 2,566 | 1,277 | 123 | - | 28.00 | 2.00 |
Cashflow From Investing | -1122.5% | -113,736 | 11,123 | -61,451 | 17,874 | -8,740 | -1,604 | 19,763 | 9,039 | 31,068 | 7,326 | -205,539 | -142,597 | -153 | - | - | - |
Cashflow From Financing | 38669.1% | 322,171 | 831 | 56,609 | 528 | 1,580 | 191 | - | 308 | 1.00 | 164 | -843 | 329,657 | 57,546 | - | - | - |
Unaudited Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Collaboration revenue | $ 1,252 | $ 2,048 |
Operating expenses: | ||
Research and development | 14,070 | 15,865 |
General and administrative | 7,343 | 6,464 |
Total operating expenses | 21,413 | 22,329 |
Loss from operations | (20,161) | (20,281) |
Other income: | ||
Interest income | 5,401 | 2,822 |
Total other income | 5,401 | 2,822 |
Net loss | (14,760) | (17,459) |
Other comprehensive gain (loss): | ||
Unrealized gain (loss) on available-for-sale securities, net | (1,189) | 796 |
Comprehensive loss | $ (15,949) | $ (16,663) |
Net loss per common share, basic | $ (0.3) | $ (0.42) |
Net loss per common share, diluted | $ (0.3) | $ (0.42) |
Weighted-average shares of common stock outstanding, basic | 49,049,741 | 41,763,971 |
Weighted-average shares of common stock outstanding diluted | 49,049,741 | 41,763,971 |
Condensed Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 212,803 | $ 19,205 |
Accounts receivable | 519 | 0 |
Short-term investments | 438,960 | 324,823 |
Prepaid expenses and other current assets | 6,384 | 5,213 |
Total current assets | 658,666 | 349,241 |
Restricted cash | 816 | 816 |
Property and equipment, net | 6,517 | 7,003 |
Operating lease right-of-use assets | 20,461 | 20,838 |
Other long-term assets | 2,524 | 2,509 |
Total assets | 688,984 | 380,407 |
Current liabilities: | ||
Accounts payable | 2,254 | 2,424 |
Accrued expenses | 5,810 | 7,387 |
Current portion of deferred revenue | 972 | 1,705 |
Current portion of operating lease liabilities | 1,573 | 1,517 |
Total current liabilities | 10,609 | 13,033 |
Operating lease liabilities, net of current portion | 22,612 | 23,025 |
Total liabilities | 33,221 | 36,058 |
Commitments and contingencies (Note 3) | ||
Stockholders’ equity (deficit): | ||
Preferred stock, $0.001 par value; authorized shares -10,000,000 at March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | ||
Common stock, $0.001 par value; authorized shares - 200,000,000 at March 31, 2024 and December 31, 2023, respectively; issued shares - 51,846,342 and 46,262,759 at March 31, 2024 and December 31, 2023, respectively; outstanding shares - 51,840,571 and 46,252,440 at March 31, 2024 and December 31, 2023, respectively | 51 | 46 |
Additional paid-in capital | 839,759 | 512,401 |
Accumulated other comprehensive income (loss) | (524) | 665 |
Accumulated deficit | (183,523) | (168,763) |
Total stockholders' equity | 655,763 | 344,349 |
Total liabilities and stockholders' equity | $ 688,984 | $ 380,407 |